GO:0046045 TMP catabolic process: Nucleotide Breakdown Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046045 (TMP catabolic process) describes the chemical reactions and pathways that break down TMP (ribosylthymine monophosphate), a thymidine nucleotide derivative.
• TMP catabolism is part of nucleotide salvage and degradation, controlling cellular pools of thymidine nucleotides needed for DNA synthesis and repair.
• Key enzymes in related pyrimidine catabolic routes include thymidine phosphorylase (TYMP), dihydropyrimidine dehydrogenase (DPYD), dihydropyrimidinase (DPYS), and beta-ureidopropionase (UPB1).
• Disruption of pyrimidine catabolism can alter drug metabolism (e.g., 5-fluorouracil) and is linked to severe toxicity in patients with DPYD deficiency.
• TMP catabolic process intersects with one-carbon metabolism, folate cycle, and mitochondrial homeostasis, making it relevant to cancer, neuroprotection, and kidney injury [2,3,8].
• CRISPR knockout, point-mutation, and knock-in models of TMP catabolic genes enable causal testing of nucleotide pool imbalance in disease phenotypes.
Description
TMP catabolic process (GO:0046045) is defined as the chemical reactions and pathways resulting in the breakdown of TMP, ribosylthymine monophosphate. TMP is a pyrimidine nucleotide that serves as a precursor for thymidine triphosphate (TTP) and is central to DNA synthesis and repair. The catabolic arm of TMP metabolism ensures that excess or damaged thymidine nucleotides are degraded to maintain nucleotide pool balance, preventing mutagenic imbalances that can drive genome instability. Understanding TMP catabolism is therefore essential for researchers studying DNA replication, chemotherapy response, and inherited metabolic disorders. The process is also clinically relevant because enzymes that degrade pyrimidines, such as thymidine phosphorylase and dihydropyrimidine dehydrogenase, influence the pharmacokinetics of fluoropyrimidine drugs like 5-fluorouracil. Moreover, TMP catabolic intermediates can feed into pathways that modulate oxidative stress and ferroptosis, as shown by studies on tetramethylpyrazine (TMP) in neuroprotection and kidney injury [2,8]. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0046045, its genes, regulation, disease links, and experimental models.
TMP catabolic process At A Glance
| GO ID | GO:0046045 |
|---|---|
| GO term | TMP catabolic process |
| Ontology | biological_process |
| Synonym | TMP breakdown; TMP catabolism; TMP degradation |
| Major function | Breakdown of TMP (ribosylthymine monophosphate) to maintain nucleotide pool balance |
| Related pathways | Pyrimidine metabolism, nucleotide salvage, one-carbon metabolism |
| Key enzymes | Thymidine phosphorylase (TYMP), dihydropyrimidine dehydrogenase (DPYD), dihydropyrimidinase (DPYS), beta-ureidopropionase (UPB1) |
| Clinical relevance | Drug metabolism (5-fluorouracil), inherited pyrimidine catabolism disorders, cancer and neuroprotection |
What Is GO:0046045?
In our own words, TMP catabolic process (GO:0046045) encompasses the enzymatic steps that convert TMP (ribosylthymine monophosphate) into downstream degradation products. This includes dephosphorylation, glycosidic bond cleavage, and further reduction or hydrolysis of the pyrimidine ring, ultimately yielding metabolites that can be excreted or reutilized. The process is part of the broader pyrimidine catabolic pathway and is critical for maintaining cellular nucleotide homeostasis.
Why Is TMP catabolic process Important in Cell Biology?
TMP catabolic process is important because it controls the cellular concentration of thymidine nucleotides, which are essential for DNA replication and repair. Imbalances in TMP catabolism can lead to nucleotide pool toxicity, increased mutagenesis, and altered sensitivity to antimetabolite drugs such as 5-fluorouracil. Additionally, enzymes in this pathway are implicated in neuroprotective and nephroprotective mechanisms, as demonstrated by studies on tetramethylpyrazine (TMP) in Alzheimer-like pathology and acute kidney injury [3,8]. Thus, understanding GO:0046045 provides mechanistic insight into cancer chemotherapy, metabolic disorders, and oxidative stress-related diseases.
• Maintains balanced thymidine nucleotide pools for faithful DNA synthesis and repair.
• Modulates the efficacy and toxicity of fluoropyrimidine chemotherapies like 5-fluorouracil.
• Links to inherited disorders of pyrimidine metabolism, including DPYD deficiency.
• Influences oxidative stress and ferroptosis pathways, as shown for TMP-related compounds.
• Plays a role in neuroprotection and Alzheimer-like pathology via tetramethylpyrazine.
• Contributes to acute kidney injury mechanisms through autophagy and YAP1-Nrf2 signaling.
• Provides targets for CRISPR-based functional genomics in cancer and metabolic disease.
• Serves as a biomarker context for drug response and personalized medicine.
What Happens During TMP catabolic process?
Dephosphorylation of TMP
In simple terms: TMP loses its phosphate group to become thymidine.
The first step in TMP catabolism often involves dephosphorylation of TMP to thymidine by nucleotidases or phosphatases. This step is not explicitly detailed in the QuickGO definition but is inferred from general pyrimidine catabolic pathways. The resulting thymidine can then be further degraded or salvaged.
Cleavage to Thymine and Deoxyribose-1-Phosphate
In simple terms: Thymidine is split into thymine and a sugar-phosphate fragment.
Thymidine phosphorylase (TYMP) catalyzes the reversible phosphorolysis of thymidine to thymine and 2-deoxy-D-ribose-1-phosphate. This enzyme is a key node in pyrimidine catabolism and is also known as platelet-derived endothelial cell growth factor, linking it to angiogenesis.
Reduction of Thymine to Dihydrothymine
In simple terms: Thymine is reduced by adding hydrogen atoms.
Dihydropyrimidine dehydrogenase (DPYD) reduces thymine to dihydrothymine using NADPH as a cofactor. This is the rate-limiting step in pyrimidine catabolism and is clinically important because DPYD deficiency causes severe toxicity to 5-fluorouracil.
Hydrolysis to Beta-Ureidoisobutyrate
In simple terms: The reduced ring is opened by adding water.
Dihydropyrimidinase (DPYS) hydrolyzes dihydrothymine to beta-ureidoisobutyrate. This step further linearizes the pyrimidine ring, preparing it for final degradation.
Final Cleavage to Ammonia, CO2, and Beta-Aminoisobutyrate
In simple terms: The molecule is broken down into waste products.
Beta-ureidopropionase (UPB1) converts beta-ureidoisobutyrate to beta-aminoisobutyrate, ammonia, and carbon dioxide. These end products can be excreted or enter other metabolic pathways.
Key Genes Involved in GO:0046045 TMP catabolic process
The following genes encode enzymes and regulators involved in TMP catabolic process and related pyrimidine degradation pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TYMP | Thymidine phosphorylase; cleaves thymidine to thymine | Angiogenesis, chemotherapy response, mitochondrial neurogastrointestinal encephalomyopathy |
| DPYD | Dihydropyrimidine dehydrogenase; reduces thymine to dihydrothymine | 5-fluorouracil toxicity, pharmacogenomics |
| DPYS | Dihydropyrimidinase; hydrolyzes dihydrothymine | Pyrimidine catabolism disorders |
| UPB1 | Beta-ureidopropionase; final cleavage step | Beta-ureidopropionase deficiency |
| NT5E | Nucleotidase; dephosphorylates TMP to thymidine | Nucleotide salvage, immune regulation |
| NT5C | Cytosolic nucleotidase; dephosphorylates pyrimidine nucleotides | Nucleotide pool homeostasis |
| SLC29A1 | Equilibrative nucleoside transporter; transports thymidine | Drug transport, chemotherapy |
| SLC29A2 | Equilibrative nucleoside transporter; transports thymidine | Nucleoside analog sensitivity |
| TK1 | Thymidine kinase 1; salvages thymidine to TMP | Cell proliferation marker, cancer |
| TK2 | Thymidine kinase 2; mitochondrial thymidine salvage | Mitochondrial DNA depletion syndromes |
| DUT | Deoxyuridine triphosphatase; prevents uracil incorporation | Genome stability, chemotherapy |
| TYMS | Thymidylate synthase; synthesizes TMP from dUMP | 5-fluorouracil target, cancer |
| MTHFR | Methylenetetrahydrofolate reductase; folate cycle | One-carbon metabolism, drug response |
| SHMT1 | Serine hydroxymethyltransferase; folate cycle | Nucleotide biosynthesis |
| MTHFD2 | Methylenetetrahydrofolate dehydrogenase; mitochondrial one-carbon | Cancer metabolism |
| GART | Phosphoribosylglycinamide formyltransferase; purine synthesis | Nucleotide biosynthesis |
| ATIC | AICAR transformylase; purine synthesis | Nucleotide biosynthesis |
How Is TMP catabolic process Regulated?
TMP catabolic process is regulated at multiple levels. DPYD expression is transcriptionally controlled and subject to pharmacogenetic variation, with DPYD deficiency leading to reduced catabolism and severe 5-fluorouracil toxicity. TYMP is regulated by hypoxia and inflammatory cytokines, linking catabolism to angiogenesis and tissue remodeling. Additionally, tetramethylpyrazine (TMP) has been shown to modulate autophagic flux via YAP1-Nrf2-p62 signaling in acute kidney injury, suggesting crosstalk between TMP-related pathways and cellular stress responses. However, direct transcriptional regulation of GO:0046045 enzymes remains an active area of research.
TMP catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DPYD | 5-fluorouracil toxicity, pyrimidine catabolism disorder | Knockout mouse, patient-derived organoids |
| TYMP | Mitochondrial neurogastrointestinal encephalomyopathy, angiogenesis | Knockout zebrafish, cell lines |
| DPYS | Dihydropyrimidinase deficiency | Patient fibroblasts, CRISPR knock-in |
| UPB1 | Beta-ureidopropionase deficiency | Knockout HEK293, mouse models |
| TK2 | Mitochondrial DNA depletion syndrome | Knockout mouse, iPSC-derived neurons |
Cancer and Chemotherapy Response
TMP catabolic enzymes influence the metabolism of fluoropyrimidine drugs. DPYD deficiency causes reduced degradation of 5-fluorouracil, leading to life-threatening toxicity. TYMP expression is associated with angiogenesis and poor prognosis in several cancers, making it a potential therapeutic target.
Neurodegeneration and Neuroprotection
Tetramethylpyrazine (TMP) has been studied for its neuroprotective effects in Alzheimer-like pathology, where it ameliorates streptozotocin-induced cognitive deficits. Additionally, TMP triazole hybrids target the KEAP1-NRF2 pathway to inhibit ferroptosis, suggesting that TMP-related catabolic processes may modulate oxidative stress in neurons.
Acute Kidney Injury
Tetramethylpyrazine attenuates sodium arsenite-induced acute kidney injury by improving autophagic flux blockade via a YAP1-Nrf2-p62-dependent mechanism. This links TMP catabolic pathways to kidney protection and autophagy regulation.
Inherited Pyrimidine Catabolism Disorders
Deficiencies in DPYD, DPYS, and UPB1 cause inherited disorders of pyrimidine metabolism, presenting with neurological symptoms, developmental delay, and drug sensitivity [4,5].
From TMP catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DPYD loss alter 5-fluorouracil sensitivity? | DPYD knockout cancer cell lines |
| Does TYMP mutation affect angiogenesis? | TYMP point-mutation knock-in endothelial cells |
| Can UPB1 deficiency be rescued by gene therapy? | UPB1 knock-in mouse model |
| How does TMP catabolism impact mitochondrial function? | TK2 knockout iPSC-derived neurons |
| Does DPYD polymorphism affect drug metabolism? | Patient-derived organoids with DPYD variants |
| Can CRISPR screen identify modifiers of TMP catabolism? | Genome-wide CRISPR knockout library in cancer cells |
How to Study the TMP catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of TMP, thymidine, thymine, dihydrothymine | Pathway activity quantification |
| CRISPR knockout screen | Gene essentiality and drug sensitivity | Identifying modifiers of TMP catabolism |
| RNA-seq | Transcriptional changes after gene editing | Compensatory pathway analysis |
| Proteomics | Protein expression and post-translational modifications | Enzyme abundance and regulation |
| Seahorse assay | Mitochondrial respiration | Metabolic impact of TMP catabolism |
| Immunofluorescence | Localization of TYMP, DPYD | Subcellular distribution |
| Flow cytometry | Cell cycle and apoptosis | Drug response phenotyping |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify genes that modulate TMP catabolic process and drug sensitivity. For example, knocking out DPYD or TYMP can reveal their roles in 5-fluorouracil response.
Metabolomics and Flux Analysis
LC-MS-based metabolomics can quantify TMP, thymidine, thymine, and downstream catabolites to assess pathway activity. Stable isotope tracing can measure flux through pyrimidine catabolism.
RNA-seq and Proteomics
Transcriptomic and proteomic profiling of cells with CRISPR edits in TMP catabolic genes can reveal compensatory changes in nucleotide metabolism and stress pathways.
Imaging and Reporter Assays
Fluorescent or luminescent reporters for thymidine nucleotides can be used to monitor TMP catabolism in live cells. Mitochondrial function can be assessed using Seahorse or JC-1 dyes.
How CRISPR Can Be Used to Study GO:0046045 TMP catabolic process
Knockout
CRISPR knockout of TMP catabolic genes such as DPYD, TYMP, DPYS, and UPB1 can create cell models to study nucleotide pool imbalance, drug sensitivity, and metabolic rewiring. These models are essential for validating gene function in disease contexts.
Point Mutation
Point mutations in DPYD (e.g., DPYD*2A) are clinically relevant for 5-fluorouracil toxicity. CRISPR point-mutation knock-in can replicate patient-specific variants in cell lines to study drug metabolism and enzyme activity.
Knock-in
Knock-in of tagged versions of TYMP or DPYD (e.g., GFP or HA tags) allows real-time tracking of enzyme localization and interactions. This is useful for understanding subcellular compartmentalization of TMP catabolism.
Overexpression
Overexpression of TYMP or DPYD via CRISPR activation or lentiviral vectors can model gain-of-function states observed in cancer. This helps determine whether increased catabolism drives angiogenesis or drug resistance.
How EDITGENE Supports TMP catabolic process Research
Researchers studying TMP catabolic process-related genes often need to determine whether a candidate gene is causally involved in nucleotide pool regulation, drug response, or disease phenotypes. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for TMP catabolic process research.
Frequently Asked Questions About TMP catabolic process
What is TMP catabolic process?
TMP catabolic process (GO:0046045) is the set of chemical reactions that break down TMP (ribosylthymine monophosphate) into thymine, dihydrothymine, and eventually beta-aminoisobutyrate, ammonia, and CO2.
What genes are involved in TMP catabolic process?
Key genes include TYMP, DPYD, DPYS, and UPB1, which encode enzymes that sequentially degrade thymidine nucleotides.
Why is TMP catabolism important for cancer?
It affects the metabolism of 5-fluorouracil; DPYD deficiency leads to severe drug toxicity, and TYMP is linked to angiogenesis [4,5].
How is TMP catabolic process regulated?
It is regulated by transcriptional control of DPYD and TYMP, and influenced by hypoxia, inflammation, and oxidative stress pathways [4,5,8].
What diseases are associated with TMP catabolic process?
Inherited deficiencies in DPYD, DPYS, and UPB1 cause pyrimidine metabolism disorders; TMP catabolism is also linked to neuroprotection and kidney injury [3,4,8].
What methods are used to study TMP catabolism?
LC-MS metabolomics, CRISPR knockout screens, RNA-seq, proteomics, and mitochondrial function assays are commonly used [5,6].
Can CRISPR be used to model TMP catabolic gene mutations?
Yes, CRISPR knockout, point mutation, and knock-in models can replicate patient-specific variants in DPYD, TYMP, and other genes [4,6].
What is the role of TYMP in TMP catabolism?
TYMP (thymidine phosphorylase) catalyzes the cleavage of thymidine to thymine and deoxyribose-1-phosphate, a key step in TMP breakdown.
How does DPYD deficiency affect drug response?
DPYD deficiency reduces thymine degradation, leading to accumulation of 5-fluorouracil and severe toxicity in patients.
What cell models are available for TMP catabolic process research?
EDITGENE offers knockout, point-mutation, knock-in, and overexpression cell models for genes in this pathway, plus CRISPR library screening.
Conclusion
TMP catabolic process (GO:0046045) is a fundamental nucleotide degradation pathway with broad implications for DNA metabolism, drug response, and disease. Understanding its enzymes and regulation can reveal new therapeutic opportunities in cancer, neurodegeneration, and metabolic disorders. EDITGENE provides the CRISPR tools and services needed to dissect this pathway with precision.
References
- 2. Li G et al.. 2025. N-butylphthalide (NBP) and ligustrazine (TMP) triazole hybrids target the KEAP1-NRF2 pathway to inhibit ferroptosis and exert brain neuroprotectivity.. Redox Biol 86:103835 PMID: 40850191
- 3. Deng C et al.. 2023. Tetramethylpyrazine ameliorates systemic streptozotocin-induced Alzheimer-like pathology.. J Chem Neuroanat 127:102207 PMID: 36470527
- 4. Xie Y et al.. 2025. Tetramethylpyrazine ameliorates 5-fluorouracil-Induced cardiotoxicity by inhibiting PANoptosis and suppressing the p38 MAPK/JNK/ERK signaling pathway.. Eur J Pharmacol 1006:178180 PMID: 40973012
- 5. Friesen WT et al.. 1981. Trimethoprim: clinical use and pharmacokinetics.. Drug Intell Clin Pharm 15(5):325-30 PMID: 7023899
- 6. Sharma N et al.. 2025. Photocontrolled trimethoprim PROTACs targeting the eDHFR protein tag.. Nat Commun 17(1):822 PMID: 41453904
- 8. Song Z et al.. 2025. Tetramethylpyrazine attenuates sodium arsenite-induced acute kidney injury by improving the autophagic flux blockade via a YAP1-Nrf2-p62-dependent mechanism.. Int J Biol Sci 21(3):1158-1173 PMID: 39897028
